-
INDIRECT TREATMENT COMPARISON OF ORFORGLIPRON AND ORAL SEMAGLUTIDE IN JAPANESE PATIENTS WITH TYPE 2 DIABETES
Aug 11, 2026, 17:16 PM -
AUTOMATED TECHNICAL VERIFICATION OF HEALTH ECONOMIC MODELS USING A GENERATIVE-AI AGENT: CONCORDANCE WITH EXPERT REVIEW ACROSS SPREADSHEET AND PROGRAMMATIC IMPLEMENTATIONS
Aug 11, 2026, 17:16 PM -
HEALTH ECONOMIC MODELING APPROACHES FOR ASSESSING THE COST-EFFECTIVENESS OF A MATERNAL GROUP B STREPTOCOCCUS VACCINATION PROGRAMME: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
EVALUATION OF AN INTERDISCIPLINARY INPATIENT WEANING PROGRAM FOR PROLONGED MECHANICAL VENTILATION: MATCHED COHORT RESULTS FROM THE "LEBENSLUFT" PROJECT
Aug 11, 2026, 17:16 PM -
ECONOMIC MODELING QUALITY AND HTA OUTCOMES: POPULATION-COVERAGE OUTCOMES AND APPRAISAL TIMELINES ACROSS NICE, CDA-AMC, AND PBAC (2020-2025)
Aug 11, 2026, 17:16 PM -
DERMATOMYOSITIS MANAGEMENT IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS OF TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION OF THE THERAPEUTIC PATHWAY WITH THE BARRX™ RADIOFREQUENCY ABLATION SYSTEM FOR BARRETT'S ESOPHAGUS, GASTRIC ANTRAL VASCULAR ECTASIA, AND RADIATION-INDUCED PROCTITIS IN THE ITALIAN NATIONAL HEALTH SERVICE
Aug 11, 2026, 17:16 PM -
THE IMPACT OF NEGATIVE BIRTH EXPERIENCE AND PERINATAL MENTAL DISORDERS ON THE QUALITY OF MOTHER-CHILD ATTACHMENT
Aug 11, 2026, 17:16 PM -
REAL-WORLD PREDICTORS OF NEOADJUVANT PEMBROLIZUMAB IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER: A UNITED STATES NATIONAL ELECTRONIC HEALTH RECORD ANALYSIS
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY AND BURDEN OF PRIMARY OPEN-ANGLE GLAUCOMA IN GERMANY: A CROSS-SECTIONAL CLAIMS DATA ANALYSIS, 2018-2024
Aug 11, 2026, 17:16 PM -
QUANTIFYING THE EPIDEMIOLOGICAL IMPACT OF ENSITRELVIR USE IN A COVID-19 PANDEMIC: AN ANALYSIS IN ITALY
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF EZETIMIBE PLUS MODERATE-INTENSITY STATIN VERSUS HIGH-INTENSITY STATIN MONOTHERAPY FOR PRIMARY PREVENTION OF ASCVD IN TAIWAN
Aug 11, 2026, 17:16 PM -
DO REGULATORY AND INNOVATION PROXIES TRANSLATE INTO HTA VALUE? EVIDENCE FROM PORTUGAL
Aug 11, 2026, 17:16 PM -
INTERNALLY VALIDATED PREDICTION OF SEVERE HEALTH UTILITY IMPAIRMENT AMONG ADULTS REPORTING DEPRESSION IN THE EU5
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFICACY AND SAFETY OF ORFORGLIPRON VS SGLT-2 INHIBITORS FOR THE TREATMENT OF INSUFFICIENTLY CONTROLLED TYPE 2 DIABETES AS AN ADD-ON TO BACKGROUND THERAPY OF 1-2 ORAL ANTIDIABETIC DRUGS: A NETWORK META-ANALYSIS
Aug 11, 2026, 17:16 PM -
WHAT DO THE FIRST EU JOINT CLINICAL ASSESSMENT COHORTS REVEAL ABOUT FUTURE EVIDENCE EXPECTATIONS? EARLY INSIGHTS FOR MANUFACTURERS AND HTA STAKEHOLDERS
Aug 11, 2026, 17:16 PM -
A POOLED REAL-WORLD CASE ANALYSIS OF BIOMARKER-GUIDED TREATMENT PATTERNS AND CLINICAL BURDEN IN BING-NEEL SYNDROME
Aug 11, 2026, 17:16 PM -
MEASURING RETURN ON INVESTMENT IN REAL-WORLD DATA, EVIDENCE, AND INSIGHTS: RESULTS FROM THE 2025 REAL-WORLD LEADERS FORUM BENCHMARK SURVEY
Aug 11, 2026, 17:16 PM -
FORGONE HEALTH FROM RESTRICTED ONCOLOGY ACCESS UNDER MOST-FAVORED-NATION PRICING: A TWO-MARGIN FRAMEWORK WITH A BREAST CANCER ILLUSTRATION
Aug 11, 2026, 17:16 PM -
DEVELOPING A MULTI-COUNTRY MICROSIMULATION TO ESTIMATE THE FUTURE IMPACT OF GUIDELINE-DIRECTED MEDICAL THERAPY ON POTENTIALLY AVOIDABLE HOSPITALISATIONS AND RELATED ECONOMIC, SOCIETAL, AND ENVIRONMENTAL OUTCOMES: GLOBALPAH
Aug 11, 2026, 17:16 PM
